On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

“New medicines can transform the way healthcare providers approach this type of blood cancer,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “We commend those who contribute to accelerating research for the benefit of patients, including those who participate in the clinical trials that lead to these approvals.”

For more information on the FDA approval of zanubrutinib (Brukinsa, BeiGene USA, Inc.), visit the FDA’s website.